---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-118261"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:31:30.017888+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BioXcel Therapeutics Q3 2024 net loss narrows to $13.7M; advances Phase 3 trials for agitation

## Summary
- Net loss of $13.7M in Q3 2024 vs $50.5M loss in Q3 2023; operating cash use $16.3M.
- IGALMI net revenue $214k in Q3, down from $341k YoY; nine-month revenue $1.9M, up 89%.
- R&D expenses $5.1M vs $19.6M; SG&A $7.7M vs $24.3M, both lower due to restructuring.
- First patient randomized in SERENITY At-Home Phase 3 trial for bipolar/schizophrenia agitation; 9-12 month duration.
- Cash and equivalents $40.4M as of Sept 30, 2024; patent portfolio extended to 2043.

## SEC filing metadata
- accession: 0001104659-24-118261
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465924118261/0001104659-24-118261-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465924118261/tm2428378d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-118261
- JSON: https://secwatch.observer/filing/0001104659-24-118261.json
- Plain text: https://secwatch.observer/filing/0001104659-24-118261.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.